Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 591

1.

Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro.

Nguyen JT, Hoopes JD, Le MH, Smee DF, Patick AK, Faix DJ, Blair PJ, de Jong MD, Prichard MN, Went GT.

PLoS One. 2010 Feb 22;5(2):e9332. doi: 10.1371/journal.pone.0009332.

2.

Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro.

Nguyen JT, Hoopes JD, Smee DF, Prichard MN, Driebe EM, Engelthaler DM, Le MH, Keim PS, Spence RP, Went GT.

Antimicrob Agents Chemother. 2009 Oct;53(10):4115-26. doi: 10.1128/AAC.00476-09. Epub 2009 Jul 20.

3.

Triple combination antiviral drug (TCAD) composed of amantadine, oseltamivir, and ribavirin impedes the selection of drug-resistant influenza A virus.

Hoopes JD, Driebe EM, Kelley E, Engelthaler DM, Keim PS, Perelson AS, Rong L, Went GT, Nguyen JT.

PLoS One. 2011;6(12):e29778. doi: 10.1371/journal.pone.0029778. Epub 2011 Dec 29.

4.

Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A viruses.

Nguyen JT, Smee DF, Barnard DL, Julander JG, Gross M, de Jong MD, Went GT.

PLoS One. 2012;7(1):e31006. doi: 10.1371/journal.pone.0031006. Epub 2012 Jan 23.

5.

Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses.

Hurt AC, Holien JK, Parker MW, Barr IG.

Drugs. 2009;69(18):2523-31. doi: 10.2165/11531450-000000000-00000.

PMID:
19943705
6.

Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants.

Ilyushina NA, Bovin NV, Webster RG, Govorkova EA.

Antiviral Res. 2006 Jul;70(3):121-31. Epub 2006 Feb 21.

PMID:
16516984
7.

Antiviral drug susceptibilities of seasonal human influenza viruses in Lebanon, 2008-09 season.

Zaraket H, Saito R, Wakim R, Tabet C, Medlej F, Reda M, Baranovich T, Suzuki Y, Dapat C, Caperig-Dapat I, Dbaibo GS, Suzuki H.

J Med Virol. 2010 Jul;82(7):1224-8. doi: 10.1002/jmv.21795.

PMID:
20513088
8.

Amantadine- and oseltamivir-resistant variants of influenza A viruses in Thailand.

Bai GR, Chittaganpitch M, Kanai Y, Li YG, Auwanit W, Ikuta K, Sawanpanyalert P.

Biochem Biophys Res Commun. 2009 Dec 18;390(3):897-901. doi: 10.1016/j.bbrc.2009.10.071. Epub 2009 Oct 20.

PMID:
19850010
9.

Neuraminidase inhibitor susceptibility of swine influenza A viruses isolated in Germany between 1981 and 2008.

Bauer K, D├╝rrwald R, Schlegel M, Pfarr K, Topf D, Wiesener N, Dahse HM, Wutzler P, Schmidtke M.

Med Microbiol Immunol. 2012 Feb;201(1):61-72. doi: 10.1007/s00430-011-0206-1. Epub 2011 Jun 19.

PMID:
21688167
10.

[Drug-resistant influenza viruses: an overview].

Hatakeyama S.

Nihon Rinsho. 2010 Sep;68(9):1671-8. Review. Japanese.

PMID:
20845746
11.

Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis--North Carolina, 2009.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2009 Sep 11;58(35):969-72.

12.

Antivirals and influenza: frequency of resistance.

Monto AS.

Pediatr Infect Dis J. 2008 Oct;27(10 Suppl):S110-2. doi: 10.1097/INF.0b013e318168b739.

PMID:
18820569
13.
14.

Antiviral management of seasonal and pandemic influenza.

Hayden FG, Pavia AT.

J Infect Dis. 2006 Nov 1;194 Suppl 2:S119-26.

15.

Evaluation of the antiviral drug susceptibility of influenza viruses in Italy from 2004/05 to 2009/10 epidemics and from the recent 2009 pandemic.

Puzelli S, Facchini M, Di Martino A, Fabiani C, Lackenby A, Zambon M, Donatelli I.

Antiviral Res. 2011 Jun;90(3):205-12. doi: 10.1016/j.antiviral.2011.04.003. Epub 2011 Apr 14.

PMID:
21514326
16.

[Susceptibility of pandemic influenza virus A 2009 H1N1 and highly pathogenic avian influenza virus A H5N1 to antiinfluenza agents in cell culture].

Fediakina IT, Shchelkanov MIu, Deriabin PG, Leneva IA, Gudova NV, Kondrat'eva TV, L'vov DK.

Antibiot Khimioter. 2011;56(3-4):3-9. Russian.

PMID:
21913403
17.

Triple-combination antiviral drug for pandemic H1N1 influenza virus infection in critically ill patients on mechanical ventilation.

Kim WY, Young Suh G, Huh JW, Kim SH, Kim MJ, Kim YS, Kim HR, Ryu YJ, Han MS, Ko YG, Chon GR, Lee KH, Choi SH, Hong SB; Korean Society of Critical Care Medicine H1N1 Collaborative.

Antimicrob Agents Chemother. 2011 Dec;55(12):5703-9. doi: 10.1128/AAC.05529-11. Epub 2011 Oct 3.

18.

Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice.

Smee DF, Hurst BL, Wong MH, Bailey KW, Morrey JD.

Antimicrob Agents Chemother. 2009 May;53(5):2120-8. doi: 10.1128/AAC.01012-08. Epub 2009 Mar 9.

19.

Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice.

Ilyushina NA, Hoffmann E, Salomon R, Webster RG, Govorkova EA.

Antivir Ther. 2007;12(3):363-70.

PMID:
17591026
20.

Inhibition of influenza virus replication by plant-derived isoquercetin.

Kim Y, Narayanan S, Chang KO.

Antiviral Res. 2010 Nov;88(2):227-35. doi: 10.1016/j.antiviral.2010.08.016. Epub 2010 Sep 6.

PMID:
20826184
Items per page

Supplemental Content

Write to the Help Desk